Cardiotoxicity in BRAF/MEK-Treated Melanoma: A Manageable but Underrecognized Risk
BRAF/MEK inhibitors improve survival in metastatic melanoma but carry a significant risk of cardiotoxicity. Our real-world study found a 21% incidence of LVEF-reduction in a Danish patient cohort, primarily within the first year. Most cases were reversible, underscoring the need for monitoring and individualized management.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen